American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition

Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology market

Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American Society of Hematology ("ASH") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming 2025 Annual Meeting.

Dr. Yulia Shifrin, Laboratory Director of Telo Genomics, will present the abstract. The contents of the abstract will also be published online in a November supplemental issue of Blood. The abstract entails Telo's Minimal Residual Disease ("MRD") clinical methodology, which combines MRD assessment with risk profiling of individual cancer cells based on the TeloView^® platform. Telo's proprietary approach to MRD is based on a non-invasive liquid biopsy and has the potential to provide best-in-class actionable information on the risk of relapse to clinicians.

Details of the abstract will be available after November 3, 2025.

The American Society of Hematology (ASH) is the world's largest professional society of clinicians and scientists dedicated to advancing the understanding, diagnosis, treatment, and prevention of blood disorders. It's upcoming 67th ASH Annual Meeting and Exposition will take place December 6-9, 2025, in Orlando, Florida.

"Acceptance at ASH 2025 represents an important acknowledgement of our technology and continued progress toward clinical adoption," said Dr. Sabine Mai, Telo's Co-Founder. "Showcasing our MRD platform at one of the most prestigious global hematology meetings highlights the growing recognition of Telo's innovation and reinforces our commitment to building long-term value and establishing a differentiated position in a growing multi-billion-dollar diagnostics market."

About MRD Assessment

Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma.